Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Belotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GLA | P06280 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Belotecan SCHEMBL29378860 | 1.00 | TOP1 (0.79) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL21410040 | 1.00 | TOP1 (0.79) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL7869454 | 0.99 | TOP1 (0.78) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL31499426 | 0.99 | TOP1 (0.78) | TOP1MEN1KMT2AALDH1A1GLA | |
| Belotecan SCHEMBL1651143 | 0.98 | TOP1 (0.76) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL2462051 | 0.92 | TOP1 (0.76) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL22843978 | 0.91 | TOP1 (0.82) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL25845670 | 0.91 | TOP1 (0.64) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL31726483 | 0.90 | TOP1 (0.72) | TOP1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5936616 | 0.90 | TOP1 (0.82) | TOP1MEN1KMT2AALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6068 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144890-A1 | ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY | MyricX Pharma Limited (GB) | 2026-05-28 | — | — | US | claimed |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| EP-4747282-A1 | ACTIVATABLE TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR (ROR) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746922-A2 | INTERLEUKIN-13 RECEPTOR SUBUNIT ALPHA-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4747283-A1 | TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR 1 (ROR1) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075733-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| US-20260137796-A1 | PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2026-05-21 | — | — | US | claimed |
| EP-4743122-A1 | THERAPEUTIC SEALANTS BASED UPON DRUG CONJUGATES | The Johns Hopkins University (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122031713-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | 乐普生物科技股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20040224986-A1 | Piperidinyl targeting compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, NV (BE) | 2004-11-11 | — | — | US | claimed |
| US-20040191250-A1 | Therapeutic liposome composition and method of preparation | ALZA CORPORATION | 2004-09-30 | — | — | US | claimed |
| US-20040191307-A1 | Therapeutic liposome composition and method of preparation | ALZA CORPORATION | 2004-09-30 | — | — | US | claimed |
| US-20030215490-A1 | Therapeutic liposome composition and method of preparation | SEQUUS PHARMACEUTICALS, INC. | 2003-11-20 | — | — | US | claimed |
| US-6465008-B1 | FOR THERAPY OF TUMORS | ALZA CORPORATION | 2002-10-15 | — | — | US | claimed |
| US-6355268-B1 | FOR CANCER CHEMOTHERAPY | ALZA CORPORATION | 2002-03-12 | — | — | US | claimed |
| CN-1323199-A | Liposome-Encapsulated Topoisomerase Inhibitors | ALZA CORP (US) | 2001-11-21 | — | — | CN | claimed |
| US-6316024-B1 | SELECTING LIPOSOME COMPRISING PRE-FORMED LIPOSOMES HAVING AN ENTRAPPED THERAPEUTIC AGENT; SELECTING TARGETING CONJUGATE COMPRISED OF LIPID HAVING A POLAR HEAD GROUP AND A HYDROPHOBIC TAIL, POLYMER, AND LIGAND; COMBINING | SEQUUS PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | claimed |
| US-20010038851-A1 | Therapeutic liposome composition and method of preparation | ALZA CORPORATION | 2001-11-08 | — | — | US | claimed |
| US-6056973-A | Therapeutic liposome composition and method of preparation | SEQUUS PHARMACEUTICALS, INC. (US) | 2000-05-02 | — | — | US | claimed |